AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15616339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 2
Study 12387773 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (groups A and C)
Number of subjects: 100
Study 12387773 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS treatment (groups B and D)
Number of subjects: 100
Study 12387773 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (groups C and D)
Number of subjects: 100
Study 10420108 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye gel containing calf blood extract
Number of subjects: 54
Study 10420108 — intervention group
Group type: COMPARATOR
Intervention: Eye ointment containing vitamin A and dexpanthenol
Number of subjects: 54
Study 8585042 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of thromboprophylaxis one week after surgery
Number of subjects: 0
Study 8585042 — intervention group
Group type: COMPARATOR
Intervention: Thromboprophylaxis
Number of subjects: 0
Study 2247864 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg beclomethasone dipropionate via metered dose inhaler alone
Number of subjects: 24
Study 2247864 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg beclomethasone dipropionate via metered dose inhaler with a 750 ml spacing device
Number of subjects: 24
Study 2247864 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 6895513 — intervention group
Group type: EXPERIMENTAL
Intervention: DSIP (delta sleep-inducing peptide)
Number of subjects: 6
Study 6895513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31859911 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII + Lira
Number of subjects: 60
Study 31859911 — intervention group
Group type: COMPARATOR
Intervention: CSII
Number of subjects: 60
Study 31922512 — intervention group
Group type: EXPERIMENTAL
Intervention: Holisal gel applied 4 times a day in the socket
Number of subjects: 30
Study 31922512 — intervention group
Group type: COMPARATOR
Intervention: Standard technique with the use of iodoform gauze
Number of subjects: 30
Study 28010936 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min distal cuff occlusion intervention (75 mmHg) at sea level
Number of subjects: 12
Study 28010936 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min distal cuff occlusion intervention (75 mmHg) at high altitude
Number of subjects: 12
Study 25737484 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 282
Study 25737484 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 282
Study 24405734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 252
Study 24405734 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemofiltration (CVVH)
Number of subjects: 252
Study 22798329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery training combined with electromyogram‐triggered electric stimulation
Number of subjects: 14
Study 22798329 — intervention group
Group type: COMPARATOR
Intervention: Generalized functional electric stimulation
Number of subjects: 14
Study 19358783 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 395
Study 19358783 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 395
Study 19358783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 395
Study 17051405 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA (estrogen + 2.5 mg medroxyprogesterone acetate)
Number of subjects: 246
Study 17051405 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (1 mg 17 beta estradiol + 0.5 mg norethindrone acetate)
Number of subjects: 246
Study 15207399 — intervention group
Group type: EXPERIMENTAL
Intervention: E. senticosus dry extract 300 mg/day
Number of subjects: 20
Study 15207399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11773815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of morphine with 75 microg of clonidine (Group M)
Number of subjects: 36
Study 11773815 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg of bupivacaine with 75 microg of clonidine (Group B)
Number of subjects: 36
Study 11773815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (M and B)
Number of subjects: 36
Study 9839098 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict target level of glycemic control (fasting capillary glucose < 6.5 mmol/l)
Number of subjects: 176
Study 9839098 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in HbA1c of 1% or more
Number of subjects: 176
Study 9839098 — intervention group
Group type: COMPARATOR
Intervention: Less strict target level of glycemic control (fasting capillary glucose < 8.5 mmol/l)
Number of subjects: 176
Study 8076623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloropropionate (2-CP) 43 mg.kg-1 body mass
Number of subjects: 6
Study 8076623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8076623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloropropionate (2-CP)
Number of subjects: 6
Study 2634922 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg. of PGE2 in 2 ml of tylose gel intracervically (group A)
Number of subjects: 106
Study 2634922 — intervention group
Group type: COMPARATOR
Intervention: 3.0 mg. of PGE2 in 5 ml of tylose gel intravaginally (group B)
Number of subjects: 106
Study 1103606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 11
Study 1103606 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 11
Study 1103606 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 30216378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery HMP (n = 10)
Number of subjects: 45
Study 30216378 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-oxygen-supplemented portal vein HMP (n = 8)
Number of subjects: 45
Study 30216378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-supplemented portal vein HMP (n = 11)
Number of subjects: 45
Study 30216378 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (n = 7)
Number of subjects: 45
Study 30216378 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-transplantable livers
Number of subjects: 45
Study 27157028 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging Horizons After School Program
Number of subjects: 112
Study 24504937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6160
Study 22325984 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS-RN
Number of subjects: 66
Study 22325984 — intervention group
Group type: COMPARATOR
Intervention: LRN
Number of subjects: 66
Study 20368393 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg laninamivir octanoate
Number of subjects: 184
Study 20368393 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg laninamivir octanoate
Number of subjects: 184
Study 20368393 — intervention group
Group type: COMPARATOR
Intervention: oseltamivir
Number of subjects: 184
Study 18584478 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low fat diet (15% of calories from fat, N = 218)
Number of subjects: 550
Study 18584478 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (30% of calories from fat, N = 332)
Number of subjects: 550
Study 18584478 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low fat diet (15% of calories from fat)
Number of subjects: 550
Study 18584478 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (30% of calories from fat)
Number of subjects: 550
Study 16150200 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule (XST), 2 capsules orally, twice a day for 8 weeks.
Number of subjects: 204
Study 16150200 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicines (mannitol, troxerutin, citicoline, piracetam, aspirin)
Number of subjects: 204
Study 16150200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 204
Study 12581252 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin (BT) injected by endoscopy in the lower esophageal sphincter (LES)
Number of subjects: 24
Study 12581252 — intervention group
Group type: COMPARATOR
Intervention: Saline injected by endoscopy in the lower esophageal sphincter (LES)
Number of subjects: 24
Study 12581252 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin (BT)
Number of subjects: 24
Study 10367822 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg/kg in fruit juice
Number of subjects: 20
Study 10367822 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg/kg in fruit juice plus antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg
Number of subjects: 20
Study 10367822 — intervention group
Group type: COMPARATOR
Intervention: Methionine-free fruit juice (placebo)
Number of subjects: 20
Study 8554933 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg orally in CF patients
Number of subjects: 11
Study 8554933 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 4 mg orally in healthy controls
Number of subjects: 11
Study 2047051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 21
Study 2047051 — intervention group
Group type: COMPARATOR
Intervention: Standard wound management protocol without aloe vera gel
Number of subjects: 21
Study 6117537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg lorazepam
Number of subjects: 60
Study 6117537 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg clobazam
Number of subjects: 60
Study 6117537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29657137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 100
Study 29657137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27084863 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dentoalveolar distractor
Number of subjects: 7
Study 27084863 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 7
Study 24952577 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PCV chemotherapy (procarbazine, CCNU, and vincristine)
Number of subjects: 447
Study 24952577 — intervention group
Group type: COMPARATOR
Intervention: Standard temozolomide (TMZ) 5-day schedule (200 mg/m2/day)
Number of subjects: 447
Study 24952577 — intervention group
Group type: COMPARATOR
Intervention: Standard temozolomide (TMZ) 21-day schedule (100 mg/m2/day)
Number of subjects: 447
Study 22265810 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message service (SMS) and Internet intervention for 12 weeks
Number of subjects: 67
Study 22265810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study 20502468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar added to a high-glycaemic index meal (mashed potatoes and low-fat milk)
Number of subjects: 16
Study 20502468 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-glycaemic index meal without vinegar)
Number of subjects: 16
Study 20502468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar added to a low-glycaemic index meal (whole grain bread, lettuce, and low-fat cheese)
Number of subjects: 16
Study 20502468 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-glycaemic index meal without vinegar)
Number of subjects: 16
Study 19196930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (14 infusions)
Number of subjects: 56
Study 16210721 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of n-3 fatty acids (FAs) intake
Number of subjects: 32470
Study 16210721 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratio of n-6 to n-3 FAs (>15:1)
Number of subjects: 32470
Study 16210721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuna consumption (2-4 servings/week)
Number of subjects: 32470
Study 16210721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuna consumption (5-6 servings/week)
Number of subjects: 32470
Study 11841402 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim) administered from 48 hours after completing chemotherapy until absolute neutrophil count exceeded 1.5 x 10(9)/l
Number of subjects: 270
Study 11841402 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G‐CSF unless severe infection occurred)
Number of subjects: 270
Study 11841402 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim)
Number of subjects: 270
Study 10735895 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TEM) 200 mg/m²/d orally for 5 days every 28 days
Number of subjects: 0
Study 10735895 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) 250 mg/m²/d IV for 5 days every 21 days
Number of subjects: 0
Study 10735895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of TEM
Number of subjects: 0
Study 10735895 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of DTIC
Number of subjects: 0
Study 10735895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis results
Number of subjects: 0
Study 10735895 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations of CE threshold
Number of subjects: 0
Study 9176076 — intervention group
Group type: EXPERIMENTAL
Intervention: Short chain fatty acid (SCFA) rectal irrigation, twice daily for six weeks
Number of subjects: 103
Study 9176076 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 103
Study 9176076 — intervention group
Group type: EXPERIMENTAL
Intervention: Short chain fatty acid (SCFA) rectal irrigation, twice daily for six weeks in patients with a short episode of colitis (< 6 months)
Number of subjects: 103
Study 9176076 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in patients with a short episode of colitis (< 6 months)
Number of subjects: 103
Study 9176076 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label SCFA treatment after the controlled trial
Number of subjects: 103
Study 1414149 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐interferon (1,000,000 IU)
Number of subjects: 16
Study 1414149 — intervention group
Group type: EXPERIMENTAL
Intervention: thymopentin (50 mg)
Number of subjects: 16
Study 1414149 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 16
Study 3551894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g in a single oral dose)
Number of subjects: 40
Study 3551894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3551894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 40
Study 30690578 — intervention group
Group type: COMPARATOR
Intervention: COMBO
Number of subjects: 78
Study 30690578 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 78
Study 29563633 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic fasting blood glucose level
Number of subjects: 17860
Study 29563633 — intervention group
Group type: COMPARATOR
Intervention: Antidiabetic drug use
Number of subjects: 17860
Study 29563633 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemic men
Number of subjects: 17860
Study 27066804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven titration tools for mealtime insulin
Number of subjects: 0
Study 25426637 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 0
Study 25426637 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling plus usual care
Number of subjects: 0
Study 25426637 — intervention group
Group type: COMPARATOR
Intervention: Counselling versus usual care
Number of subjects: 0
Study 25426637 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23713218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongravity dependent flywheel device (RAD)
Number of subjects: 8
Study 23713218 — intervention group
Group type: COMPARATOR
Intervention: Commercially available rowing ergometer (C2)
Number of subjects: 8
Study 20624802 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based educational intervention for parents to wean children from the bottle over 1 week
Number of subjects: 251
Study 20624802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 251
Study 18546240 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 2201
Study 16641218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 84
Study 16641218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 12632354 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia (0.25% bupivicaine, 1 mL/kg)
Number of subjects: 46
Study 10756410 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (TPM)
Number of subjects: 0
Study 8973788 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg
Number of subjects: 52
Study 8973788 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 20 mg
Number of subjects: 52
Study 8973788 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 40 mg
Number of subjects: 52
Study 8973788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1426204 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 9
Study 1426204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1426204 — intervention group
Group type: COMPARATOR
Intervention: Control (no premedication)
Number of subjects: 9
Study 31028598 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT intervention
Number of subjects: 111
Study 31028598 — intervention group
Group type: COMPARATOR
Intervention: No access to ADAPT intervention
Number of subjects: 111
Study 28934781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position (Group L)
Number of subjects: 68
Study 28934781 — intervention group
Group type: COMPARATOR
Intervention: Prone position (Group P)
Number of subjects: 68
Study 26070123 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor in women with GH or mild PE at term
Number of subjects: 756
Study 26070123 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum predictors
Number of subjects: 756
Study 26070123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum predictors
Number of subjects: 756
Study 26070123 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models
Number of subjects: 756
Study 24107763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for PTSD, 8 once-weekly sessions
Number of subjects: 13
Study 21317177 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00547,659 (0.03-10 mg/kg IV/SC, single or multiple doses at 4-week intervals)
Number of subjects: 80
Study 21317177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19429529 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise tests under normoxic conditions
Number of subjects: 23
Study 19429529 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise tests under hypoxic conditions
Number of subjects: 23
Study 19429529 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical correlation analysis (CCA)
Number of subjects: 23
Study 17901847 — intervention group
Group type: EXPERIMENTAL
Intervention: Planecta SC(R) (PNSC)
Number of subjects: 162
Study 17901847 — intervention group
Group type: COMPARATOR
Intervention: Conventional three-way stopcock
Number of subjects: 162
Study 15801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Told Nicotine
Number of subjects: 49
Study 15801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Told No Nicotine
Number of subjects: 49
Study 15801579 — intervention group
Group type: COMPARATOR
Intervention: No Spray
Number of subjects: 49
Study 11786865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 0
Study 11786865 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 0
Study 11786865 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 0
Study 9538963 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA)‐enriched weight‐reducing formula diet
Number of subjects: 17
Study 9538963 — intervention group
Group type: COMPARATOR
Intervention: Low‐fat, high‐CHO weight‐reducing formula diet
Number of subjects: 17
Study 8080348 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, 0.4 mg/kg
Number of subjects: 14
Study 8080348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2686740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms PGE1
Number of subjects: 20
Study 2686740 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms PGE1
Number of subjects: 20
Study 2686740 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 2686740 — intervention group
Group type: COMPARATOR
Intervention: Preservative
Number of subjects: 20
Study 17894080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol 5 mg
Number of subjects: 50
Study 17894080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol 2 mg
Number of subjects: 50
Study 17894080 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol 1 mg
Number of subjects: 50
Study 17894080 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine 25 mg
Number of subjects: 50
Study 17894080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31142530 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular points acupressure (AA)
Number of subjects: 60
Study 31142530 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular points acupressure (sham AA)
Number of subjects: 60
Study 28839339 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (VBZ) 1, 2, 5, or 12.5 mg (Cohort 1) and 12.5, 25, 50, or 75 mg (Cohort 2) single doses
Number of subjects: 32
Study 28839339 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (VBZ) 75, 100, 125 or 150 mg single doses
Number of subjects: 32
Study 28839339 — intervention group
Group type: COMPARATOR
Intervention: Valbenazine (VBZ) 50 or 100 mg once-daily for 8 days (Cohort 1)
Number of subjects: 32